199 related articles for article (PubMed ID: 15629202)
1. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders.
Youdim MB; Buccafusco JJ
Trends Pharmacol Sci; 2005 Jan; 26(1):27-35. PubMed ID: 15629202
[TBL] [Abstract][Full Text] [Related]
2. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
Barchet TM; Amiji MM
Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
[TBL] [Abstract][Full Text] [Related]
3. CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases.
Youdim MB; Buccafusco JJ
J Neural Transm (Vienna); 2005 Apr; 112(4):519-37. PubMed ID: 15666041
[TBL] [Abstract][Full Text] [Related]
4. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
Chen JF; Chern Y
Handb Exp Pharmacol; 2011; (200):267-310. PubMed ID: 20859800
[TBL] [Abstract][Full Text] [Related]
5. The emergence of designed multiple ligands for neurodegenerative disorders.
Geldenhuys WJ; Youdim MB; Carroll RT; Van der Schyf CJ
Prog Neurobiol; 2011 Sep; 94(4):347-59. PubMed ID: 21536094
[TBL] [Abstract][Full Text] [Related]
6. Catechin polyphenols: neurodegeneration and neuroprotection in neurodegenerative diseases.
Mandel S; Youdim MB
Free Radic Biol Med; 2004 Aug; 37(3):304-17. PubMed ID: 15223064
[TBL] [Abstract][Full Text] [Related]
7. Polycyclic cage structures as lipophilic scaffolds for neuroactive drugs.
Joubert J; Geldenhuys WJ; Van der Schyf CJ; Oliver DW; Kruger HG; Govender T; Malan SF
ChemMedChem; 2012 Mar; 7(3):375-84. PubMed ID: 22307951
[TBL] [Abstract][Full Text] [Related]
8. Neurotrophic factors and neurodegenerative diseases: a delivery issue.
Ruozi B; Belletti D; Bondioli L; De Vita A; Forni F; Vandelli MA; Tosi G
Int Rev Neurobiol; 2012; 102():207-47. PubMed ID: 22748832
[TBL] [Abstract][Full Text] [Related]
9. Inefficient central nervous system delivery limits the use of ibuprofen in neurodegenerative diseases.
Mannila A; Rautio J; Lehtonen M; Järvinen T; Savolainen J
Eur J Pharm Sci; 2005 Jan; 24(1):101-5. PubMed ID: 15626583
[TBL] [Abstract][Full Text] [Related]
10. [Review on the neuroprotective effects of green tea polyphenols for the treatment of neurodegenerative diseases].
Li Q; Li Y
Wei Sheng Yan Jiu; 2010 Jan; 39(1):123-6. PubMed ID: 20364607
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. The cholinergic system, sigma-1 receptors and cognition.
van Waarde A; Ramakrishnan NK; Rybczynska AA; Elsinga PH; Ishiwata K; Nijholt IM; Luiten PG; Dierckx RA
Behav Brain Res; 2011 Aug; 221(2):543-54. PubMed ID: 20060423
[TBL] [Abstract][Full Text] [Related]
13. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
Hol EM; Fischer DF; Ovaa H; Scheper W
Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotection from complement-mediated inflammatory damage.
Kulkarni AP; Kellaway LA; Lahiri DK; Kotwal GJ
Ann N Y Acad Sci; 2004 Dec; 1035():147-64. PubMed ID: 15681806
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnological applications for the treatment of neurodegenerative disorders.
Modi G; Pillay V; Choonara YE; Ndesendo VM; du Toit LC; Naidoo D
Prog Neurobiol; 2009 Aug; 88(4):272-85. PubMed ID: 19486920
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease.
Avramovich-Tirosh Y; Amit T; Bar-Am O; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2007 Jan; 100(2):490-502. PubMed ID: 17144902
[TBL] [Abstract][Full Text] [Related]
17. Targeting JNK3 for the treatment of neurodegenerative disorders.
Resnick L; Fennell M
Drug Discov Today; 2004 Nov; 9(21):932-9. PubMed ID: 15501728
[TBL] [Abstract][Full Text] [Related]
18. Designing drugs with multi-target activity: the next step in the treatment of neurodegenerative disorders.
Geldenhuys WJ; Van der Schyf CJ
Expert Opin Drug Discov; 2013 Feb; 8(2):115-29. PubMed ID: 23231597
[TBL] [Abstract][Full Text] [Related]
19. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders.
Sas K; Robotka H; Toldi J; Vécsei L
J Neurol Sci; 2007 Jun; 257(1-2):221-39. PubMed ID: 17462670
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
